Proteome Sciences (LON:PRM) Stock Price Up 16.3% – Time to Buy?

Proteome Sciences plc (LON:PRM)’s stock price was up 16.3% during mid-day trading on Friday . The company traded as high as GBX 1.50 and last traded at GBX 1.50. Approximately 210,243 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 411,285 shares. The stock had previously closed at GBX 1.29.

Proteome Sciences Trading Up 16.3%

The company has a debt-to-equity ratio of -165.46, a current ratio of 0.13 and a quick ratio of 0.37. The stock has a market capitalization of £5.26 million, a price-to-earnings ratio of -1.33 and a beta of 0.07. The business has a 50 day simple moving average of GBX 1.64 and a 200-day simple moving average of GBX 2.

Proteome Sciences (LON:PRM) last posted its earnings results on Wednesday, April 15th. The company reported GBX (1.04) earnings per share (EPS) for the quarter. Proteome Sciences had a negative net margin of 81.50% and a positive return on equity of 33.80%. The business had revenue of GBX 376 million during the quarter.

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.